Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
CHMP February 2026 Approvals: 12 New Medicines and Biosimilars Advance
The CHMP Febru...
EMA’s mCombriax Vaccine Recommendation
EMA's mCombriax Vaccine Recommendation Ushers in Dual Protection Era
The mCombriax vaccine recommendation from the European Medicines Agency (EMA) marks a milestone for individuals aged 50 and older. EMA has recomm...
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC
FDA Greenlights HERNEXEOS Lung Cancer Treatment as First-Line Option
HERNEXEOS lung cancer treatment (zongertinib tablets), developed by